海思科(002653.SZ)：获得创新药HSK45019片IND申请受理

Core Viewpoint - The announcement indicates that the company’s subsidiary, Shanghai Hisun Shennuo Pharmaceutical Technology Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the drug "HSK45019 tablets," which is a novel treatment option for inflammatory bowel disease patients [1]. Group 1 - The drug HSK45019 is a small molecule inhibitor developed independently by the company and possesses independent intellectual property rights [1]. - HSK45019 is expected to provide a new and effective treatment option for patients suffering from inflammatory bowel disease, enhancing convenience and efficacy in treatment [1]. - According to the National Medical Products Administration's announcement regarding the classification of chemical drug registration, HSK45019 falls under Class 1 chemical drugs [1].